Less Ads, More Data, More Tools Register for FREE

Pin to quick picksVenture Life Regulatory News (VLG)

Share Price Information for Venture Life (VLG)

London Stock Exchange
Share Price is delayed by 15 minutes
Get Live Data
Share Price: 39.50
Bid: 39.00
Ask: 40.00
Change: 0.50 (1.28%)
Spread: 1.00 (2.564%)
Open: 39.00
High: 39.50
Low: 39.00
Prev. Close: 39.00
VLG Live PriceLast checked at -

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

New distribution agreements

23 Sep 2014 07:00

RNS Number : 3099S
Venture Life Group PLC
23 September 2014
 

 

Venture Life Group plc

("Venture Life" or "the Group")

Long-term distribution agreements signed with four new partners

 

Bracknell, UK - 23 September 2014: Venture Life Group plc (AIM: VLG), the international consumer self-care group addressing the needs of the ageing population, announces that it has signed long-term product distribution agreements with four new partners. The agreements give these distributors exclusive rights to sell certain Venture Life products across a total of nine European territories, including Germany. Based on the contractual minimum purchase obligations of the partners, these four agreements combined should deliver minimum annual revenues of €0.24 million in year 1, rising to €0.59 million in year 5, and totalling €5.1 million over the ten year term of the agreements.

 

The agreements are with the following companies:

 

Distributor

Venture Life product

Territories

Expected first revenues for VLG

Valeant

Procto-eze cream

Six, including Germany

H1 2015

Lyfis

Procto-eze cream and cleanser

Iceland

H1 2015

Symphar

Procto-eze cream

Poland

H1 2015

Deltapharma

Original Bioscalin shampoo and capsules

Albania

H1 2015

 

In addition to these agreements, the Group has already signed a further seven product partnering deals during 2014, as well as four extension deals signed with existing partners for additional Venture Life products. The Group now has distribution agreements covering all 14 of its current branded products in a combined 42 territories worldwide, and its unbranded products manufactured by Biokosmes are sold in over 10 countries.

Jerry Randall, Chief Executive Officer of Venture Life, commented:

"We are delighted to broaden further our partner base in Europe, and to see further validation of our model and products through a long term agreement with Valeant, a global top 50 pharmaceutical company. We are delivering increasing benefits from the merger with Biokosmes and are seeing gathering momentum in our branded portfolio as we broaden the distribution base of our branded products. We are particularly pleased with our first distribution deal in Germany, the fourth largest economy in the world and a major European territory".

 

- Ends -

 

For further information please contact:

Venture Life Group PLC

Jerry Randall, Chief Executive Officer

James Hunter, Chief Financial Officer +44 (0)1344 742 870

 

 

Square1 Consulting

David Bick

Mark Longson +44 (0)20 7929 5599

 

 

JW Communications

Julia Wilson +44 (0)7818 430877

 

 

Notes to editors

 

About Venture Life

Venture Life is an international consumer self-care company focused on developing, manufacturing and commercializing products for the ageing population. The Group's product range and pipeline currently include food supplements for lowering cholesterol and maintaining brain function, dermo-cosmetics for addressing the signs of ageing, and medical devices for improving minor aches and pains, dry eyes and itchy skin. The products, which typically are recommended by pharmacists or healthcare practitioners, are available primarily through pharmacies supplied by the Group's international distribution partners.

 

Through its topical development and manufacturing business, Biokosmes, the Group also provides development and manufacturing services to companies in the medical device and cosmetic sectors.

The Group's own branded products are currently sold or partnered in over 50 countries and currently include:

· food supplements to maintain brain function and memory;

· dermo-cosmetics for addressing the signs of skin ageing and hair loss, and

· medical devices for improving conditions such as minor aches and pains, dry eyes and itchy skin.

 

The Company has a healthy development pipeline including products in areas such as diabetes, cardiovascular health, obesity, cognitive function and skin ageing. Products coming from the pipeline will be expected to have intellectual property protection and be supported by independent clinical evidence of efficacy.

 

About Procto-eze

Procto-eze helps relieve the discomfort caused by haemorrhoids.

 

About Original Bioscalin

Original Bioscalin helps control hair loss, promotes new hair growth and enhances the overall condition of hair.

 

 

This information is provided by RNS
The company news service from the London Stock Exchange
 
END
 
 
NRADLLFLZKFFBBX
Date   Source Headline
17th May 20227:00 amRNSFinal Results
10th May 202211:31 amRNSExercise of Share Options & Voting Rights
19th Apr 20227:00 amRNSReporting Update
23rd Mar 20223:00 pmRNSAnnouncement re: Full year results
22nd Feb 20227:00 amRNSGrant of Options and PDMR Dealing
21st Feb 20227:00 amRNSResults - clinical trial led by Cardiff University
31st Jan 20224:41 pmRNSSecond Price Monitoring Extn
31st Jan 20224:37 pmRNSPrice Monitoring Extension
31st Jan 20222:06 pmRNSSecond Price Monitoring Extn
31st Jan 20222:01 pmRNSPrice Monitoring Extension
31st Jan 20227:00 amRNSTrading Statement
24th Jan 20222:06 pmRNSSecond Price Monitoring Extn
24th Jan 20222:00 pmRNSPrice Monitoring Extension
10th Jan 20227:00 amRNSBusiness Update
29th Dec 202112:34 pmRNSDirector/PDMR Shareholding
20th Dec 20214:13 pmRNSDirectorate Change
14th Dec 202111:05 amRNSSecond Price Monitoring Extn
14th Dec 202111:01 amRNSPrice Monitoring Extension
3rd Dec 20214:22 pmRNSDirector/PDMR Shareholding
1st Dec 20219:06 amRNSSecond Price Monitoring Extn
1st Dec 20219:00 amRNSPrice Monitoring Extension
1st Dec 20217:00 amRNSTrading Update & Board Changes
1st Nov 20212:00 pmRNSPrice Monitoring Extension
1st Nov 20218:44 amRNSHolding(s) in Company
1st Nov 20218:43 amRNSHolding(s) in Company
25th Oct 20217:00 amRNSHolding(s) in Company
11th Oct 20212:41 pmRNSHolding(s) in Company
23rd Sep 20219:05 amRNSSecond Price Monitoring Extn
23rd Sep 20219:00 amRNSPrice Monitoring Extension
23rd Sep 20217:00 amRNSHalf-year Report
7th Sep 20211:54 pmRNSHolding(s) in Company
13th Aug 20219:05 amRNSSecond Price Monitoring Extn
13th Aug 20219:00 amRNSPrice Monitoring Extension
13th Aug 20217:00 amRNSTrading Update and Progress on recent Acquisitions
6th Aug 20217:00 amRNSAcquisition of Oncology Support Product Assets
21st Jun 20217:00 amRNSRevolving Credit Facility
7th Jun 20217:00 amRNSAcquisition of BBI Healthcare Limited
20th May 20212:29 pmRNSResult of AGM
14th Apr 20214:19 pmRNSHolding(s) in Company
25th Mar 20212:19 pmRNSConfirmation of AGM Date
25th Mar 20217:00 amRNSFinal Results
25th Feb 20217:00 amRNSInvestor Presentation
1st Feb 20217:00 amRNSTrading Update & Notice of Results
14th Dec 20202:07 pmRNSIssue of Equity
11th Dec 20207:27 amRNSHolding(s) in Company
10th Dec 20204:45 pmRNSHolding(s) in Company
10th Dec 20204:41 pmRNSHolding(s) in Company
10th Dec 20202:42 pmRNSHolding(s) in Company
10th Dec 20201:45 pmRNSHolding(s) in Company
9th Dec 20202:28 pmRNSDirector/PDMR Shareholding

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.